ADAmber Davis

Amber Davis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amber Davis has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Role of Respiratory Viral Infections in Airflow Obstruction After Hematopoietic Cell Transplantation

    by Sapna A. Pardasani, Ali Y. Suliman, Jose A. Ferrolino, Ronald H. Dallas, Megan Peterson, Pamela Merritt, Amanda Cole, Amber Davis, Ashleigh Gowen, Kim J. Allison, et al.

    Background: Respiratory viral infections (RVIs) in allogeneic hematopoietic cell transplant (allo‐HCT) recipients can cause airflow obstruction (AFO). Despite this risk, the impact of community‐acquired RVI on PFTs in pediatric patients after allo‐HCT remains unclear. Objective: The study determines the role of RVI in the development of AFO post‐transplant among survivors of allo‐HCT. Study Design: This retrospective study analyzed St. Jude patients undergoing allo‐HCT between 2003–2020. AFO was defined by z ‐scores and forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio expressed as lower limit of normal (LLN). Baseline parameters were obtained before allo‐HCT, and Year 1 parameters within 425 days post allo‐HCT. Spirometry measures were calculated using the global lung function Initiative (GLI) calculator. Bivariate and multivariate logistic regression identified risk factors for AFO following allo‐HCT. Results: A total of 397 patients were included, with a median age of 12.7 years. RVI occurred in 13% of patients within the first 100 days after transplantation. AFO developed in 12% of patients. Among those with AFO, 68% had a baseline FEV1/FVC ratio above the LLN, and 11% had a history of lower respiratory tract infection (LRTI) ( p < 0.05). The median time from transplant to RVI was shorter in patients with AFO (12 vs. 34 days). A baseline LLN value was a significant predictor of AFO. However, after adjusting for known covariates, RVI was not independently associated with AFO risk. Conclusion: RVIs within 100 days of allo‐HCT did not significantly affect AFO following transplant in pediatric patients.

  • Open Access

    Early Discontinuation of Empiric Antibiotics in Pediatric Haploidentical Hematopoietic Cell Transplant Recipients With Febrile Neutropenia

    by Sandra Castejon-Ramirez, Diego R Hijano, Rachel L Wattier, Jose Ferrolino, Megan Peterson, Pamela Merritt, Amber Davis, Amanda Cole, Kim J Allison, Ashleigh Gowen, et al.

    Background: Febrile neutropenia (FN) is common in children, adolescents, and young adults (CAYA) undergoing hematopoietic cell transplant (HCT), particularly following allogeneic haploidentical HCT (haplo-HCT). Optimal empiric antibiotic duration for FN is not well established in this population. Methods: A retrospective quasi-experimental study was conducted among CAYA undergoing haplo-HCT between 2010 and 2022 who experienced FN. In 2017 a guideline was implemented for discontinuation of empiric antibiotics within 72 hours of FN in patients without identified infection regardless of persistence of fever. We compared patients who underwent haplo-HCT preimplementation (Pre-I) versus postimplementation (Post-I) of this guideline. The primary outcome was days of therapy (DOT). Secondary outcomes included incidence of bloodstream infections (BSI), intensive care unit (ICU) admission, and mortality from 72 hours of FN onset until neutrophil engraftment. A desirability of outcome ranking (DOOR) with a modified response adjusted for duration of antibiotic risk (RADAR) approach using DOT was applied to comprehensively assess outcomes. Results: Patients in the Post-I group (n = 82) had fewer DOT compared to Pre-I (n = 90) with a median difference of 8 days (P < .01). There were no significant differences in BSI incidence, ICU admission, or mortality between groups. The DOOR–modified RADAR analysis demonstrated that Post-I was associated with a 70% (95% confidence interval, 61%–78%) probability of experiencing a more favorable clinical outcome compared to Pre-I (P < .01). Conclusions: Early antibiotic discontinuation appears safe and feasible in CAYA haplo-HCT recipients with FN, significantly reducing antibiotic exposure without increasing adverse outcomes. Large prospective multicenter trials are needed to confirm these findings.